Resveratrol Enhances the Antiproliferative Effect of GLUT-1 Inhibition in Lung Cancer Models.
X. Multidisciplinary Cancer Research Congress, Eskişehir, Türkiye, 8 - 11 Mayıs 2025, ss.180, (Özet Bildiri)
- Yayın Türü: Bildiri / Özet Bildiri
- Basıldığı Şehir: Eskişehir
- Basıldığı Ülke: Türkiye
- Sayfa Sayıları: ss.180
- Bursa Uludağ Üniversitesi Adresli: Evet
Özet
Introduction and Aim: Lung cancer remains one of the leading causes of cancer-related mortality worldwide, largely due to late-stage diagnosis and limited treatment efficacy. A key hallmark of tumor progression is metabolic reprogramming, including enhanced glucose uptake to sustain rapid proliferation. Glucose transporter 1 (GLUT-1), frequently overexpressed in lung cancer, plays a central role in this metabolic shift and has been associated with poor prognosis. Targeting GLUT-1-mediated glucose transport represents a promising therapeutic strategy. Resveratrol, a polyphenolic compound found in red fruits, possesses antioxidant, anti-inflammatory, and antiproliferative properties. Due to its structural similarity to tyrosine kinase inhibitors, Resveratrol has been proposed to modulate GLUT-1 activity and impair glucose metabolism in cancer cells. This study aimed to investigate the combined effect of GLUT-1 inhibition and Resveratrol on the viability and proliferation of lung cancer cells. Materials and Methods: Human A549 and murine Lewis Lung Carcinoma (LLC-1) cell lines were used as models. Cells were treated in four groups: control (DMSO), GLUT-1 inhibitor, Resveratrol, and the combination of both agents. Viability was assessed using the Sulforhodamine B (SRB) assay. Synergistic interactions were evaluated via combination index (CI) analysis. The most effective dose combination was further assessed with time-dependent viability and colony formation assays. Results: Combined treatment with GLUT-1 inhibitor and Resveratrol led to a significant synergistic reduction in cell viability in both cell lines. The combination of 6 µM Resveratrol and 20 µM GLUT-1 inhibitor yielded the strongest effect, with a CI of 0.59, indicating marked synergism. Growth inhibition increased up to 5.5-fold compared to single-agent treatments. Discussion: These findings suggest that concurrent inhibition of GLUT-1 and Resveratrol treatment exerts a synergistic antitumor effect in lung cancer cells, supporting its potential as a novel therapeutic strategy. Key words: Lung cancer, GLUT-1 inhibition, Resveratrol, Metabolic reprogramming, Synergistic therapy